Lung India最新文献_第2页

Inhaled antibiotics and non-cystic fibrosis bronchiectasis: Trying to solve the puzzle. 吸入抗生素和非囊性纤维化支气管扩张：试图解决这个难题。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_608_24

Nithiyanandan Ravi

{"title":"Inhaled antibiotics and non-cystic fibrosis bronchiectasis: Trying to solve the puzzle.","authors":"Nithiyanandan Ravi","doi":"10.4103/lungindia.lungindia_608_24","DOIUrl":"10.4103/lungindia.lungindia_608_24","url":null,"abstract":"Bronchiectasis is a chronic airway disease with recurrent exacerbations and hospitalisations. No inhaled antibiotic has shown consistently beneficial effects in trials. This review analyses the evidence on inhaled antibiotics in non-cystic fibrosis bronchiectasis (NCFB), identifies patient traits for their use, and highlights research gaps. A PubMed search for \"Inhaled antibiotics AND bronchiectasis\" identified five inhaled antibiotics studied in randomised controlled trials (RCTs): aztreonam, tobramycin, gentamycin, ciprofloxacin, and colistin. Inhaled antibiotics reduced exacerbation frequency, sputum bacterial density, and increased bacterial eradication but did not improve lung function. They also increased antimicrobial resistance, with aztreonam and aminoglycosides having higher discontinuation rates due to side effects. Increased sputum bacterial density (>107 colony forming units/g), increased exacerbation frequency (≥4) at baseline, and increased sputum volume and/or purulence at baseline are some of identifiable traits associated with benefit from inhaled antibiotics. Inhaled antibiotics may aid in eradicating Pseudomonas aeruginosa after first isolation in NCFB, but their role in acute exacerbations requires further research. There are no direct RCTs comparing different delivery systems, antibiotics, and regimens.","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 5","pages":"443-455"},"PeriodicalIF":1.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12453535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144974213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xantho-granulomatous pleuritis: A rare histopathological entity with diagnostic and therapeutic challenges. 黄斑肉芽肿性胸膜炎：一种罕见的组织病理实体，诊断和治疗具有挑战性。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_313_25

Shabana Andleeb Ansari, Sanjay Kumar Kannaujia, Beant Kaur, Ruovinuo Sachu

引用次数: 0

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_591_24

Anitha M Barney, Barney Isaac, Balamugesh Thangakunam, Sumita Danda, Debashish Danda, Venkata R Mohan, Christhunesa S Christudass, Devasahayam J Christopher

{"title":"Health-related quality of life (HRQoL) and its predictors among patients with Idiopathic pulmonary fibrosis attending a tertiary care setting in Southern India.","authors":"Anitha M Barney, Barney Isaac, Balamugesh Thangakunam, Sumita Danda, Debashish Danda, Venkata R Mohan, Christhunesa S Christudass, Devasahayam J Christopher","doi":"10.4103/lungindia.lungindia_591_24","DOIUrl":"10.4103/lungindia.lungindia_591_24","url":null,"abstract":"Background and objectives: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive Interstitial lung disease (ILD) that has a significant impact on the health-related quality of life (HRQoL). There are generic and disease-specific questionnaires to assess this, but no literature from India exists.Hence we decided: to estimate HRQoL and to determine its predictors in a cohort of patients attending a tertiary care centre in Southern India.Methods: Consecutive consenting patients diagnosed with IPF by the ILD MDD between September 2023 and August 2024 were self-administered the St. George's Respiratory Questionnaire (SGRQ) and the King's Brief Interstitial Lung Disease (KBILD) questionnaire to assess the HRQoL.Results: In all, 70 patients with IPF were recruited into the study. The median total SGRQ was 35.9 (23.9-57.8), and the median total KBILD was 54.5 (46.4-65.6). Based on SGRQ (>30), 63% (44/70) and based on KBILD (≤50), 34% (24/70) had a poor quality of life. The SGRQ was significantly lower in those not on antifibrotics across all domains, with a trend towards near significance in the activity domain. The Gender, Age, Physiology (GAP) Index had a significant association with the KBILD - breathlessness and activity domain (P value = 0.01) and the total score (P value = 0.02).Conclusion: This is the first Indian study reporting HRQoL in IPF. IPF impacts HRQoL drastically, with a predominant impact on physical wellness and a lesser effect on psychological well-being. KBILD is associated with the GAP index. A larger study is required to identify independent factors associated with HRQoL.","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 5","pages":"421-428"},"PeriodicalIF":1.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12453537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144974210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Re use of EBUS needles: The elephant in the room. 勘误：EBUS针的重复使用：房间里的大象。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_617_25

引用次数: 0

Bronchoscopic management of endobronchial hamartomas using "hot and cold" therapies - Initial experience in two patients. 支气管镜下治疗支气管内错构瘤的“冷热”疗法-两例患者的初步经验。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_622_24

Manu Chopra, Gaurav Mishra, Rahul Tyagi, Kislay Kishore, Aseem Yadav, Ritwik Chakrabarti, Monika Aggarwal

{"title":"Bronchoscopic management of endobronchial hamartomas using \"hot and cold\" therapies - Initial experience in two patients.","authors":"Manu Chopra, Gaurav Mishra, Rahul Tyagi, Kislay Kishore, Aseem Yadav, Ritwik Chakrabarti, Monika Aggarwal","doi":"10.4103/lungindia.lungindia_622_24","DOIUrl":"10.4103/lungindia.lungindia_622_24","url":null,"abstract":"Pulmonary hamartomas are the most common benign tumours of the lung and are often detected incidentally. Endobronchial hamartomas, though rare, can cause significant symptoms such as dyspnoea, haemoptysis, and recurrent respiratory infections due to bronchial obstruction. This report describes the successful bronchoscopic management of symptomatic endobronchial hamartomas in two young Indian males aged 29 and 34 years. Both cases were diagnosed based on radiological and histopathological findings. The first patient underwent eight sessions of electrocautery fulguration using a flexible bronchoscope, while the second was treated with six sessions of cryotherapy delivered through a flexible bronchoscope guided cryoprobe. All procedures were carried out under conscious sedation via nasal insertion of the flexible bronchoscope, with no requirement for rigid bronchoscopy or general anaesthesia. Both patients showed marked symptomatic improvement and near-complete resolution of endobronchial lesions. Follow-up bronchoscopies at 18 and 12 months, respectively, revealed no recurrence, and no procedure-related complications were observed. These cases highlight the safety, efficacy, and minimally invasive nature of flexible bronchoscopic techniques such as electrocautery and cryoablation in managing endobronchial hamartomas, particularly in settings where surgical options may be limited.","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 5","pages":"456-460"},"PeriodicalIF":1.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12453540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144974086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bird's nest sign - revisited. 鸟巢的标志-重新审视。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_593_24

Karanam Gowrinath, Pothula Madhurima

引用次数: 0

A comparative study of clinical profile and oxidative stress in smokers and non-smokers with COPD. 慢性阻塞性肺病吸烟者和非吸烟者临床特征和氧化应激的比较研究。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_42_25

Saradhapriya Subbaiyan, Pajanivel Ranganadin, Rajesh Srinivasan, Agieshkumar Balakrishna Pillai, Balaji Balu

引用次数: 0

Yield of systematic screening for tuberculosis among patients with obstructive airway disease using inhalational corticosteroids. 吸入性糖皮质激素对阻塞性气道疾病患者肺结核的系统性筛查效果。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_602_24

Manju Rajaram, Palanivel Chinnakali, Vinayagamoorthy Venugopal, Mahesh B Vemuri, Archana Malik, Noyal M Joseph

{"title":"Yield of systematic screening for tuberculosis among patients with obstructive airway disease using inhalational corticosteroids.","authors":"Manju Rajaram, Palanivel Chinnakali, Vinayagamoorthy Venugopal, Mahesh B Vemuri, Archana Malik, Noyal M Joseph","doi":"10.4103/lungindia.lungindia_602_24","DOIUrl":"10.4103/lungindia.lungindia_602_24","url":null,"abstract":"Introduction: The increased risk of tuberculosis associated with inhalation corticosteroids has been demonstrated in various studies. However, the specific risk factors for developing tuberculosis in this context are less studied. So, this study was planned.Methods: This cross-sectional study was carried out in the Department of Pulmonary Medicine of a tertiary care centre in Puducherry, India. Those patients who were on inhalational corticosteroid for more than 1 year and having presumptive TB symptom were included in the study. Sputum smears, chest radiography, and CBNAAT were done in all cases of presumptive tb cases, and bronchoscopies and BAL where necessary were used to diagnose patients. The patient was diagnosed with tuberculosis diagnosis upon microbiologic confirmation.Results: 1550 patients had symptoms of presumptive tuberculosis and were thus included in the study. The mean age of our study population was 50.97 ± 19.25. Male gender, use of higher doses of steroids, coronary artery disease, smoking, and alcohol use were the risk factors for the development of tuberculosis. On multivariate regression analysis, diabetes (OR: 6.4, 95% CI: 2.275-18.121, P value: 0.001) and higher doses of steroid use (OR: 7, 95% CI: 2.485-20.026, P value: 0.001) were identified as independent risk factors for the development of tuberculosis among patients using inhalational corticosteroids. The number indeed to screen was 262.Conclusion: Patients who were on higher doses of inhalational corticosteroids and diabetic patients should be advised to undergo targeted screening and testing for tuberculosis. In order to get one case tuberculosis patient, we have to screen 262 cases of OAD patients.","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"42 5","pages":"414-420"},"PeriodicalIF":1.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12453532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144974177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thoracic ultrasonography in the diagnosis and follow-up of lung abscess. 胸部超声在肺脓肿诊断及随访中的应用。

IF 1.2

Lung India Pub Date : 2025-09-01 Epub Date: 2025-09-02 DOI: 10.4103/lungindia.lungindia_11_25

Göksel Menek, Coşkun Doğan

引用次数: 0

Cone beam computed tomography-guided bronchoscopic sampling of peripheral pulmonary lesions: The first Indian experience. 锥形束计算机断层扫描引导支气管镜下肺周围病变取样：首次印度经验。

IF 1.2

Lung India Pub Date : 2025-07-15 DOI: 10.4103/lungindia.lungindia_92_25

Venkata Nagarjuna Maturu, Vipul Kumar Garg, Virender Pratibh Prasad, Rinoosha Rachel, Kishan Srikanth Juvva, Sai Sindhu Kotla

{"title":"Cone beam computed tomography-guided bronchoscopic sampling of peripheral pulmonary lesions: The first Indian experience.","authors":"Venkata Nagarjuna Maturu, Vipul Kumar Garg, Virender Pratibh Prasad, Rinoosha Rachel, Kishan Srikanth Juvva, Sai Sindhu Kotla","doi":"10.4103/lungindia.lungindia_92_25","DOIUrl":"10.4103/lungindia.lungindia_92_25","url":null,"abstract":"Background: Conventional bronchoscopic approaches have a lower diagnostic yield (DY) compared to transthoracic biopsy for sampling peripheral pulmonary lesions (PPLs). Cone-beam computed tomography (CBCT)-guided bronchoscopy overcomes the limitations of conventional bronchoscopy techniques. This study evaluates DY, predictors of success, and safety of CBCT-guided bronchoscopy for PPL biopsy.Materials and methods: This single-center retrospective study included all consecutive patients who underwent CBCT-guided biopsy for PPLs between November 2023 and November 2024. Clinico-radiologic and procedural details, tool-in-lesion (TIL) relationships, DY, factors predicting DY, and complications were assessed.Results: Of the 183 patients who underwent bronchoscopic sampling of PPL during study period, 50 patients underwent CBCT-guided biopsy. The overall DY of CBCT biopsy was 88% (44/50). A type 1 TIL (tool within lesion) was obtained in 57% (28/49), type 2 TIL (tool touch lesion) in 35% (17/49), and a type 3 TIL (tool away from lesion) in four cases. The factors predicting DY were size of lesion and the tool-lesion relationship. DY increased with increasing size of PPL and decreased the farther the tool was from the center of the target. The DY was 100%, 82%, and 25% for lesions with type 1, type 2, and type 3 TIL, respectively ( P = 0.024). CBCT biopsy was safe with no procedural mortality, no pneumothorax, and moderate to severe bleed in seven cases.Conclusion: CBCT-guided biopsy for peripheral pulmonary lesions is safe and has a DY of 88%. DY is higher for lesions ≥2 cm and when the tool is within the lesion (type 1 TIL) on CBCT spin.","PeriodicalId":47462,"journal":{"name":"Lung India","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0